Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07396623

Validation of French PHQ-4 and PC-PTSD-5 Screening Scales

Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD).

Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Avicenne

Bobigny, 93000, France

Location status: Recruiting

Location contact

Anne Mottais, Doctor

PRINCIPAL_INVESTIGATOR

Gaelle Colevray

CONTACT

[email protected]

Gaëlle Colevray, Medical student

PRINCIPAL_INVESTIGATOR

Nicolas Vignier, Professor

PRINCIPAL_INVESTIGATOR

Vladimir ADRIEN, Doctor

CONTACT

[email protected]

+33148955421

Vladimir Adrien, Doctor

PRINCIPAL_INVESTIGATOR

About this study

A target of 10 patients per item of the tested scales was set. The PHQ-4 includes four items and the PC-PTSD-5 includes five items, corresponding to required sample sizes of 40 and 50 patients, respectively. Although the same patient sample completes both scales, these sample sizes were combined to account for potential loss to follow-up and to optimize statistical power, resulting in a total inclusion target of 90 patients.

Descriptive analyses of sociodemographic and clinical characteristics will be conducted for all included patients. Quantitative variables will be summarized using means and standard deviations, and qualitative variables using frequencies and percentages.

To address the primary objective, convergent validity will be assessed using Pearson's correlation coefficients between scores obtained on the tested scales (PHQ-4 and PC-PTSD-5) and those obtained on their respective gold standard instruments (PHQ-9, GAD-7, and PCL-5). Convergent validity will also be examined by inclusion center through comparison of correlation coefficients across centers.

Secondary objectives will be addressed through:

  • Exploratory factor analysis to examine the dimensional structure of each scale and to compare it with that of the corresponding gold standard.
  • Assessment of internal consistency using Cronbach's alpha coefficient. Test-retest reliability will be evaluated using the intraclass correlation coefficient on a subsample of at least 20 participants, depending on the final total sample size, who will complete the PHQ-4 and PC-PTSD-5 scales twice.
  • Evaluation of diagnostic performance by calculating sensitivity and specificity for each scale among patients undergoing a psychiatric diagnostic assessment, with receiver operating characteristic (ROC) curves generated for each scale.
  • Assessment of feasibility based on the time required to complete both scales.

All statistical tests will be two-sided and considered statistically significant at an alpha level of 0.05.

No statistical imputation methods will be used for the management of missing data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years,
  • Outpatient or hospitalized for any health-related reason,
  • Oral and written proficiency in French,
  • Patient informed and willing to participate in the study,
  • Patient with health insurance coverage

Exclusion criteria

  • Individuals under legal protection measures (guardianship, conservatorship, or legal supervision),
  • Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders

Treatment and study plan

Primary outcomes

  1. Assess the validity of the French version of the PHQ-4 (Patient Health Questionnaire-4 ) scale

    Time frame: 14 days

    This scale is used for the screening of anxiety and depression. The scale will be scored.

    Score ranging from 0 to 12, corresponding to four levels of psychological distress:

    • None: 0-2
    • Mild: 3-5
    • Moderate: 6-8
    • Severe: 9-12 Patients will complete this scale at Visit 1 and Visit 2.
  2. Assess the validity of the French version of the PC-TDSD-5 (Primary Care PTSD Screen for DSM-5) scale

    Time frame: 14 days

    Scale assessing whether the patient has experienced unusually or particularly frightening, horrible, or traumatic events. Examples include:

    • A serious accident or fire
    • Physical or sexual assault, or sexual abuse
    • An earthquake or flood
    • War
    • Witnessing a person being killed or seriously injured
    • The death of a close person by homicide or suicide Total score = sum of "YES" responses to questions 1 through 5. Patients will complete this scale at Visit 1 and Visit 2.

Secondary outcomes

  1. Assess the feasibility of this screening tool during the first evaluation visit.

    Time frame: At Visit 1 (at inclusion)

    The time required for the patient to complete each scale (individually) will be timed and recorded (without informing the patient in order to avoid potential stress).

Study contacts

Contact information is provided by the study sponsor or research team.

Vladimir ADRIEN, Doctor

CONTACT

[email protected]

(+33) 1 48 95 59 37

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Validation of the French Versions of the PHQ-4 Anxiety and Depression Scale and the PC-PTSD-5 Post-Traumatic Stress Disorder Screening Scale

Acronym: DEPSYSTAGE

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 9, 2026
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.